In the publication of International Publication No. 01/40227, it is reported that the compounds represented by formula (I) regulate the effect of chemokine/chemokine receptor, so they are used for prevention and/or treatment of various inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases (allergic bronchopulmonary aspergillosis or allergic eosinophilic gastroenteritis etc.), nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, psoriasis, rhinitis, conjunctivitis, ischemic reperfusion disorder, multiple sclerosis, ulcerative colitis, acute respiratory distress syndrome, cytotoxic shock, diabetes, autoimmune disease, in transplanted organ rejection reactions, immunosuppression, cancer metastasis and acquired immune deficiency syndrome. Furthermore, in the specification, the inhibition effect on the binding of RANTES to CCR5 and the inhibition effect on the binding of MCP-1 to CCR2 had been found experimentally. However, the test which indicates that the compounds represented by formula (I) are used for actual HIV infection has never been described.
Furthermore, in the specification, a combination of chemokine/chemokine regulator with other drugs has never been described.